Cartesian Therapeutics, Inc. (RNAC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7495 New Horizon Way
Frederick, MD 21703
United States of America (the)
Phone
617 923 1400
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
June 22, 2016
| Name | Title | Pay | Year Born |
| Carsten Brunn | President, Chief Executive Officer & Chairman of the Board | 1.04M | 1971 |
| Milos Miljkovic | Chief Medical Officer | 569,443 | 1984 |
| Emily English | Chief Operating Officer | 589,814 | 1980 |
| Blaine T. Davis | Chief Financial Officer | 693,345 | 1974 |
| Peter G. Traber | Head of R&D | 2.76M | 1955 |
| Matthew Bartholomae | General Counsel & Secretary | 0 | N/A |
| June Seymour | Chief Accounting Officer | 0 | 1978 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.